StockData
BioStem Technologies, Inc. logo

BioStem Technologies, Inc. (BSEM) stock

BSEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$0.64−0.07 (-10.23%)

Close on Nov 20, 2026Market cap $11.34MP/E –Yield –

Earnings

BioStem Technologies's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2026
$7.60M
EPS, Q3 FY2026
-$0.64
Latest guidance
Issued
Nov 12, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of BioStem Technologies's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 12, 2026after the close$7.60M–-$0.64Release
Q2 FY2026ended Jun 30, 2026Aug 12, 2026after the close$7.90M–-$0.52Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

BioStem Technologies's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenueGAAPFY2026$28.00M – $29.00M–NewNov 12, 2026
revenueFY2026$26.00M – $29.00M–NewAug 12, 2026

Guidance history

Every forecast BioStem Technologies put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 12, 2026revenueFY2026$28.00M – $29.00MNew
Aug 12, 2026revenueFY2026$26.00M – $29.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases BioStem Technologies filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?